Author:
Leipold Angelyn,Grupa Taylor,Swanoski Michael
Abstract
The Food and Drug Administration issued several warnings recently regarding the use of fluoroquinolones because of a variety of serious toxicities. Risk for serious adverse reactions increases in older people because of the physiologic changes that come with aging, the increased likelihood
of concurrent comorbidities, and the use of multiple medications. Because of these risk-enhancing factors, fluoroquinolone use, particularly in older people, should be scrutinized and used only when no other therapeutic alternatives exist. Pharmacists can have an impact on fluoroquinolone
prescribing and use; therefore, they can optimize patient outcomes by reducing the potential for harm caused by fluoroquinolone use in older people.
Publisher
American Society of Consultant Pharmacists
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献